Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANI Pharmaceuticals, Inc.

http://www.anipharmaceuticals.com/

Latest From ANI Pharmaceuticals, Inc.

Rocket Pharmaceuticals’ CEO Talks Gene Platforms and Spiritual Leadership

The trajectory of Rocket Pharmaceuticals, a clinical-stage gene therapy company, has been marked by a series of impressive milestones. At least partial credit for those accomplishments goes to CEO Gaurav Shah, who co-founded the company in 2015 and has combined scientific, business and managerial savvy to progress the company through two regulatory filings this year. Shah recently spoke to In Vivo about the company and his own leadership style.

C-Suite Speaks Interviews

AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition

The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.

M & A Companies

Digital Health Roundup: HLTH2022 Highlights, EU Updates, Diabetes Medtech Monthly

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb provides highlights from the recent HLTH conference in Las Vegas. Reed Miller and Barnaby Pickering offer an overview of the highly competitive diabetes tech market. We also talk about digital health in Germany and Europe.

Digital Health Innovation

AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy

The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.

M & A Cancer
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Services
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • BioSante Pharmaceuticals, Inc.
    • Cell Genesys, Inc.
    • Novitium Pharma LLC
UsernamePublicRestriction

Register